Skip to main content

Navigation group

Type at least 3 characters
210 articles

Articles

Original Research

Published on 22 Feb 2023

Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data

in Pediatric Rheumatology

  • Ekaterina Alexeeva
  • Elizaveta Krekhova
  • Tatyana Dvoryakovskaya
  • Ksenia Isaeva
  • Aleksandra Chomakhidze
  • Evgeniya Chistyakova
  • Olga Lomakina
  • Rina Denisova
  • Anna Mamutova
  • Anna Fetisova
Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data
Frontiers in Pediatrics
doi 10.3389/fped.2023.1114207
  • 2,718 views
  • 8 citations